logo/base Created with Sketch.
See product brochures

Fast

Identification of at-risk MASH* patients

Fast is a FibroScan®-based Score

chevron chevron

Fast Target

Current developments in MASH treatments focus on patients with MASH who are at risk of progressing to cirrhosis or who have compensated cirrhosis, defined as Active Fibrotic MASH (MASH + NAS ≥ 4 + F ≥ 2).

Read The Lancet publication on Fast

Fast Construction

Fast combines FibroScan® examination results (LSM by VCTE® & CAP) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-MASH at the point of care, thereby reducing the need for invasive and costly procedures.

Read The Lancet publication on Fast

Fast Performance

Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast.

Read The Lancet publication on Fast

Our liver health solutions

  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron

  • Agile 3+

    Identification of advanced fibrosis in MASLD patients

    chevron

  • Agile 4

    Identification of cirrhosis in patients with MASLD

    chevron
  • FibroScan® Mini+ 430

    FibroScan® by echosens

    The non-invasive solution for comprehensive management of liver health

    chevron

Fast: tried and trusted

Improvements in Fast are consistent with amelioration of key histologic features of MASH, including both inflammation and fibrosis.

Publication Boursier et al.

Oral ILC (EASL) 2020 : Abstract AS075

Fast score demonstrated good discrimination for fibrotic MASH in our cohort.

Publication Anand et al.

European Journal of Gastroenterology & Hepatology, 2020.

I believe that Fast is a key element for MASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.

Yusuf Yilmaz

Professor and M.D. Gastroenterology and Hepatology, Turkey

Discover the clinical evidence chevron

Request a demo!

Interested in FibroScan®?

Contact us

Fast is an algorithm intended to aid in the diagnosis of active fibrotic Non-Alcoholic Steatohepatitis (NASH) in patients with suspected Non-Alcoholic Fatty Liver Disease (NAFLD). Fast is used, during liver assessment, in patient with suspected NAFLD. Fast is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and healthcare issues, it is not a substitute for or replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions. The following precautions must be observed when using Fast: LSM (also known as E) and CAP measurements must come from the same FibroScan® examination; There must be no more than 6 months between the FibroScan® examination and the blood sample necessary for AST assessment. Fast must not be used in the following situations : pregnancy, patients under 18 years old, chronic or acute liver diseases other than NAFLD, liver transplant patients, cardiac failure and/or significant vascular disease, confirmed diagnosis of active malignancy or other terminal disease, use of treatment inducing liver injury.

*MASLD/MASH is formerly knowed as NAFLD/NASH

To access the Fast User Guides, connect to myfibroscan.com:
Scores > Fast > Learn more

chevron User Guides Fast